Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis:Is the evidence of sufficient quality to develop recommendations?

BACKGROUND The standard management of autoimmune hepatitis(AIH) is based on corticosteroids, alone or in combination with azathioprine. Second-line treatments are needed for patients who have refractory disease. However, high-quality data on the alternative management of AIH are scarce.AIM To evaluate the efficacy and safety of tacrolimus and mycophenolate mofetil(MMF) and the quality of evidence by using the Grading of Recommendations Assessment, Development and Evaluation approach(GRADE).METHODS A systematic review and meta-analysis of the available data were performed. We calculated pooled event rates for three outcome measures: Biochemical remission, adverse events, and mortality, with their corresponding 95% confidence intervals(CI).RESULTS The pooled biochemical remission rate was 68.9%(95%CI: 60.4-76.2) for tacrolimus, and 59.6%(95%CI: 54.8-64.2) for MMF, and rates of adverse events were 25.5%(95%CI: 12.4-45.3) for tacrolimus and 24.1%(95%CI: 15.4-35.7) for MMF. The pooled mortality rate was estimated at 11.5%(95%CI: 7.1-18.1) for tacrolimus and 9.01%(95%CI: 6.2-12.8) for MMF. Pooled biochemical remission rates for tacrolimus and MMF in patients with intolerance to standard therapy were 56.6%(CI: 43.4-56.6) vs 73.5%(CI: 58.1-84.7), and among non-responders were 59.1%(CI: 48.7-68.8) vs 40.8%(CI: 32.3-50.0), respectively. Moreover, the overall quality assessments using GRADE proved to be very low for all our outcomes in both treatment groups.CONCLUSION Tacrolimus and MMF are in practice considered effective for patients with AIH who are non-responders or intolerant to first-line treatment, but we found no high-quality evidence to support this statement.